EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Proton Pump Inhibitors: Vonoprazan as a New Standard in Helicobacter pylori Eradication

Divyasri Gurrala, Ratna kumari Padamati

International Journal of Educational Innovations and Research · 08.03.2026 · 2 (1) · 30-47

DOI: 10.63671/ijeir.v2i1.86 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Educational Innovations and Research, online erschienen am 08.03.2026. Verfasst von Divyasri Gurrala und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Helicobacter pylori remains a significant global health burden, driving chronic gastritis, peptic ulcer disease, and gastric cancer. Conventional proton pump inhibitor (PPI)-based eradication therapies have shown declining efficacy due to rising antimicrobial resistance, variable acid suppression, and adherence challenges. Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), offers rapid, potent, and sustained acid inhibition independent of meal timing or CYP2C19 metabolism. Clinical trials and meta-analyses demonstrate superior or non-inferior eradication rates compared to PPI-based regimens, particularly in clarithromycin-resistant infections, with favourable safety and tolerability profiles. Real-world studies support its effectiveness, adherence benefits, and cost-effectiveness across healthcare systems. Vonoprazan-based dual, triple, and quadruple therapies are increasingly integrated into regional and international guidelines, with fixed-dose formulations and paediatric programmes under development. Future directions include broader global access, long-term safety monitoring, and exploration of novel delivery platforms. Overall, vonoprazan represents a paradigm shift in H. pylori management, providing a reliable alternative to PPIs and addressing key limitations of current eradication strategies.

Zitieren

APA

Gurrala, D., & Padamati, R. K. (2026). Beyond Proton Pump Inhibitors: Vonoprazan as a New Standard in Helicobacter pylori Eradication. International Journal of Educational Innovations and Research, 2(1), 30-47. https://doi.org/10.63671/ijeir.v2i1.86

Vancouver

Gurrala D, Padamati RK. Beyond Proton Pump Inhibitors: Vonoprazan as a New Standard in Helicobacter pylori Eradication. International Journal of Educational Innovations and Research. 2026;2(1):30-47. doi:10.63671/ijeir.v2i1.86

BibTeX
@article{Gurrala2026,
  author = {Gurrala, Divyasri and Padamati, Ratna kumari},
  title = {Beyond Proton Pump Inhibitors: Vonoprazan as a New Standard in Helicobacter pylori Eradication},
  journal = {International Journal of Educational Innovations and Research},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {30--47},
  doi = {10.63671/ijeir.v2i1.86}
}
Kostenlos starten →